Short article about the difference between the COVID-19 antiviral pills made by Merck and Pfizer mentions ISMP’s January 3, 2022, alert that patients with severe renal impairment should not receive the drug, while those with moderate renal impairment should receive a dose reduction.
For the full text, visit Becker’s Hospital Review online.
More News
Nonprofit patient safety organization releases annual list of 10 patient safety threats in conjunction with Patient Safety Awareness week, March 10 to 16
This article appeared on the MyChesCo website on February 26, 2024.
New Items Focus on Tranexamic Acid, Transitions in Care, and Vaccines